Cargando…
Optimizing the evaluation of gene-targeted panels for tumor mutational burden estimation
Though whole exome sequencing (WES) is the gold-standard for measuring tumor mutational burden (TMB), the development of gene-targeted panels enables cost-effective TMB estimation. With the growing number of panels in clinical trials, developing a statistical method to effectively evaluate and compa...
Autores principales: | Li, Yawei, Luo, Yuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548549/ https://www.ncbi.nlm.nih.gov/pubmed/34702927 http://dx.doi.org/10.1038/s41598-021-00626-7 |
Ejemplares similares
-
Influence of low tumor content on tumor mutational burden estimation by whole‐exome sequencing and targeted panel sequencing
por: Zhang, Wenxin, et al.
Publicado: (2021) -
Designing gene panels for tumor mutational burden estimation: the need to shift from ‘correlation’ to ‘accuracy’
por: Wu, Hao-Xiang, et al.
Publicado: (2019) -
Tumor mutational burden quantification from targeted gene panels: major advancements and challenges
por: Fancello, Laura, et al.
Publicado: (2019) -
The Tumor Mutational Burden of Chinese Advanced Cancer Patients Estimated by a 381-cancer-gene Panel
por: Zhuang, Wu, et al.
Publicado: (2018) -
Tumor mutation burden derived from small next generation sequencing targeted gene panel as an initial screening method
por: Tang, Yuan, et al.
Publicado: (2020)